Detailed Narrative
Challenging Q1 FY26 Performance Amidst Headwinds
Aarti Industries reported a challenging Q1 FY26 with revenue at ₹1,867 crore, marking a 16% QoQ decline, and EBITDA at ₹215 crore, a 19% QoQ decline. Profit After Tax stood at ₹43 crore. The quarter was significantly impacted by a steep 15-20% correction in key input prices like benzene and aniline, leading to ₹30 crore in inventory valuation losses, and global trade disruptions.
Impact of Geopolitical and Domestic Disruptions
The Israel-Iran conflict in May/June 2025 caused ripple effects on global logistics, leading to shipping delays and rerouting of some exports, with an estimated ₹15-20 crore EBITDA deferment. Domestically, India-Pakistan tensions in April-May 2025 briefly impacted operations at the Kutch facility and caused temporary shutdowns at Kandla Port, further straining outbound volumes and curtailing capacity utilization.
Strategic Capacity Expansions and Ramp-up
The company continued its capacity ramp-up for Nitrotoluene (from 30 to 45 KTPA) and Ethylation (from 10 to 30 KTPA). Additionally, MMA capacity was scaled up from 200 KTPA to 260 KTPA. These facilities are now in the ramp-up phase, positioned to meet rising demand in end applications, and are part of initiatives to optimize inventory and costs.
Zone IV and Multipurpose Plant (MPP) Commissioning Timelines
Zone IV projects are progressing well, with phased commercialization expected from H2 FY26. The first phase, including the multipurpose plant and a calcium chloride unit, is targeted for commissioning by December 2025. The remaining five blocks are scheduled for phase-wise commissioning from January to May 2026, with these new products expected to achieve a 20%+ EBITDA margin profile.
Potential Impact of New US Tariffs
New US announcements of a 25% tariff on Indian imports, along with an unspecified 'penalty,' pose a potential impact on Aarti Industries' US business, which accounts for 15-20% of its revenues. Management is actively monitoring the situation, assessing the impact across different product lines (e.g., positive for phenylenediamine, negative for DCB and MMA), and developing mitigation measures while exploring new markets.
Capital Allocation and Debt Management
Capex for Q1 FY26 was ₹280 crore, with the full-year guidance for FY26 set below ₹1,000 crore, a reduction from the previous year's ₹1,300-1,400 crore. The company aims to reduce its net debt by ₹200-300 crore in FY26 from its peak of ₹3,500 crore, benefiting from a softer interest rate regime. Working capital increased temporarily due to deferred shipments and delayed receivables.
Segmental Performance and Outlook
The energy segment saw flattish volumes due to plant disruptions, while non-energy applications showed mixed performance. DCB volumes declined significantly due to lower demand from US automotive customers and inventory liquidation, though recovery is expected in H2 FY26. Agrochemical intermediates continue to face pricing pressure, with a longer timeframe anticipated for realization improvements.